GT199900039A - Combinaciones de estatina-inhibidor de mmp. - Google Patents

Combinaciones de estatina-inhibidor de mmp.

Info

Publication number
GT199900039A
GT199900039A GT199900039A GT199900039A GT199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A
Authority
GT
Guatemala
Prior art keywords
statin
mmp inhibitor
inhibitor combinations
frague
fleasure
Prior art date
Application number
GT199900039A
Other languages
English (en)
Inventor
Roger Schofield Newton
Bruce David Roth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900039A publication Critical patent/GT199900039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCIÒN PROPORCIONA UN MÈTODO DE TRATAMIENTO Y PREVENCIÒN DE LA INSUFICIENCIA CARDÌACA Y OTRAS ENFERMEDADES VASCULARES EN UN MAMÌFERO, QUE COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN INHIBIDOR DE METALOPROTEINASA DE MATRIZ JUNTO CON UNA ESTATINA (VER FÒRMULA I & II ADJUNTAS, LAS LETRAS "A" Y "R" REPRESENTAN POSIBLES GRUPOS FUNCIONALES QUE PUEDEN SER SUSTITUIDOS Y CUYO LISTADO ESPECÌFICO PUEDE LEERSE EN EL DOCUMENTO ORIGINAL).
GT199900039A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp. GT199900039A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
GT199900039A true GT199900039A (es) 2000-09-06

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900039A GT199900039A (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp.

Country Status (18)

Country Link
EP (1) EP1063991A1 (es)
JP (1) JP2002506818A (es)
KR (1) KR20010041916A (es)
AR (1) AR018113A1 (es)
AU (1) AU1591699A (es)
BR (1) BR9815745A (es)
CA (1) CA2309588A1 (es)
CO (1) CO5070670A1 (es)
GT (1) GT199900039A (es)
HN (1) HN1999000029A (es)
MY (1) MY140504A (es)
NZ (1) NZ505994A (es)
PA (1) PA8469001A1 (es)
PE (1) PE20000348A1 (es)
SV (1) SV1999000026A (es)
UY (1) UY25436A1 (es)
WO (1) WO1999047138A1 (es)
ZA (1) ZA992106B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
EP2310417A4 (en) * 2008-07-11 2012-01-11 Forskarpatent I Syd Ab FOR OXIDIZED LDL SPECIFIC ANTIBODY FUSION AND CONJUGATED PROTEINS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
SK282863B6 (sk) * 1996-05-17 2002-12-03 Warner-Lambert Company Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze
JP2001526631A (ja) * 1996-12-09 2001-12-18 ワーナー−ランバート・コンパニー 心不全および心拡張症の治療および予防方法
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
CO5070670A1 (es) 2001-08-28
KR20010041916A (ko) 2001-05-25
UY25436A1 (es) 2001-10-25
SV1999000026A (es) 2000-01-18
PA8469001A1 (es) 2002-09-17
NZ505994A (en) 2003-10-31
CA2309588A1 (en) 1999-09-23
EP1063991A1 (en) 2001-01-03
BR9815745A (pt) 2000-11-14
AR018113A1 (es) 2001-10-31
JP2002506818A (ja) 2002-03-05
WO1999047138A1 (en) 1999-09-23
MY140504A (en) 2009-12-31
AU1591699A (en) 1999-10-11
ZA992106B (en) 1999-09-30
HN1999000029A (es) 1999-09-29
PE20000348A1 (es) 2000-05-22

Similar Documents

Publication Publication Date Title
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
BR9812879A (pt) Lente oftálmica
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
EA199800667A1 (ru) Новые фенантридины
HU9603328D0 (en) Retroviral protease inhibitor combinations
ATE234091T1 (de) Thrombin inhibitoren
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
DE69625230T2 (de) Thrombininhibitoren
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
GT199900039A (es) Combinaciones de estatina-inhibidor de mmp.
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
PT1187612E (pt) Utilizacao do riluzole para o tratamento da esclerose multipla
IT8919735A0 (it) Procedimento per la riduzione del cod da reflui industriali o urbani.
NO20005548L (no) Mykobakterieinhibitorer
DE68920757D1 (de) Lysyl-Oxidase-Inhibitoren.
NO995849D0 (no) Aldehydfritt desinfeksjonsmiddel for overflater og instrumenter
AR034375A1 (es) Combinacion de un inhibidor de ptpasa y un agente de sulfonilurea
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
DK0828483T3 (da) Anvendelse af tropolonderivater som inhibitorer af enzymet inositolmonophosphatase
BR0112460A (pt) Método para tratamento de sépsis
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
ECSP951559A (es) Inhibidores de la 5- lipoxigenasa
ECSP992885A (es) Combinaciones de estatina-inhibidor de mmp
SE9402855L (sv) Trappstegsmatare